Encompass Health Corporation Stock

Equities

EHC

US29261A1007

Healthcare Facilities & Services

Market Closed - Nyse 04:00:02 2024-04-12 pm EDT 5-day change 1st Jan Change
80.49 USD -1.43% Intraday chart for Encompass Health Corporation -3.44% +20.64%
Sales 2024 * 5.26B Sales 2025 * 5.7B Capitalization 8.06B
Net income 2024 * 396M Net income 2025 * 441M EV / Sales 2024 * 2 x
Net Debt 2024 * 2.47B Net Debt 2025 * 2.36B EV / Sales 2025 * 1.83 x
P/E ratio 2024 *
20.7 x
P/E ratio 2025 *
18.6 x
Employees 23,832
Yield 2024 *
0.75%
Yield 2025 *
0.75%
Free-Float 85.59%
More Fundamentals * Assessed data
Dynamic Chart
As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal CI
Encompass Health Plans to Build 50-Bed Rehabilitation Hospital in San Antonio MT
Encompass Health Corp. Announces Preliminary Plans to Build Freestanding, 50-Bed Inpatient Rehabilitation Hospital in San Antonio CI
Barclays Raises Price Target on Encompass Health to $101 From $95, Maintains Overweight Rating MT
Encompass Health Corporation Appoints Andrew Baird as Senior Vice President of Public Policy, Legislation and Regulations CI
Transcript : Encompass Health Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM
Encompass Health Corp. and Piedmont Announce Plans to Build 40-Bed Inpatient Rehabilitation Hospital in Loganville, Georgia CI
Encompass Health Maintains Quarterly Dividend at $0.15 per Share, Payable April 15 to Holders of Record April 1 MT
Encompass Health Corporation Declares Quarterly Cash Dividend, Payable on April 15, 2024 CI
Encompass Health to Build 60-Bed Arizona Rehab Hospital for Severe Injury Recovery MT
Encompass Health Corporation Announces Preliminary Plans to Build a 60-Bed Inpatient Rehabilitation Hospital in Avondale, Arizona CI
UBS Adjusts Encompass Health Price Target to $88 From $84, Maintains Buy Rating MT
Mizuho Raises Price Target on Encompass Health to $82 From $77, Keeps Buy Rating MT
Deutsche Bank Adjusts Encompass Health Price Target to $83 From $77, Maintains Buy Rating MT
Transcript : Encompass Health Corporation, Q4 2023 Earnings Call, Feb 08, 2024
More news
1 day-1.43%
1 week-3.44%
Current month-2.53%
1 month+4.60%
3 months+16.75%
6 months+28.60%
Current year+20.64%
More quotes
1 week
80.47
Extreme 80.47
83.17
1 month
74.27
Extreme 74.27
83.73
Current year
65.99
Extreme 65.99
83.73
1 year
57.55
Extreme 57.55
83.73
3 years
44.33
Extreme 44.33
89.68
5 years
44.33
Extreme 44.33
89.68
10 years
30.26
Extreme 30.26
89.68
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 92-12-31
Director of Finance/CFO 63 10-05-05
Chief Tech/Sci/R&D Officer 64 -
Members of the board TitleAgeSince
Director/Board Member 69 13-01-24
Director/Board Member 61 19-12-31
Chief Executive Officer 62 92-12-31
More insiders
Date Price Change Volume
24-04-12 80.49 -1.43% 611,053
24-04-11 81.66 +0.11% 489,804
24-04-10 81.57 -0.46% 652,336
24-04-09 81.95 -0.44% 548,072
24-04-08 82.31 -1.26% 630,978

Delayed Quote Nyse, April 12, 2024 at 04:00 pm EDT

More quotes
Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides specialized rehabilitative treatment on an inpatient basis. It operates hospitals in 37 states and Puerto Rico, with concentrations in Florida and Texas. It operates 161 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. The Company provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals also treat patients with or recovering from the COVID-19 virus. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
80.49 USD
Average target price
88.55 USD
Spread / Average Target
+10.01%
Consensus